- CYD-TDV (Dengvaxia)
- DENVax
- TetraVax-DV
- Others
Dengue Vaccine Market size was valued at USD 472.6 million in 2023 and is poised to grow at a significant CAGR of 12.8% from 2024-2030. As per the World Health Organization, the frequency of dengue has become significant over ongoing many years. A larger part of the cases are asymptomatic, gentle, or independent, and thus the genuine number of diseases are exceptionally under-announced. One displaying gauge demonstrates 390 million dengue diseases each year (95% valid span 284-528 million), of which 96 million show clinically. This report studies market dynamics elaborately to identify the current trends & drivers, future opportunities, and possible challenges to the key stakeholders operating in the market.
Global Dengue Vaccine Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
12.8%
Largest Market
Asia Pacific
Fastest Growing Market
North America
Dengue Vaccine Market Dynamics
Dengue fever or breakbone fever is caused by four distinct, virus serotypes, which are transmitted to humans by Aedes aegypti mosquito. Dengue fever is epidemic in several countries of Asia-pacific and Latin America region. The growing global epidemic of dengue in aforementioned regions is expected to create demand for the dengue vaccine over the forecast period. Increasing initiatives from local governments and World Health Organization (WHO) to curb the dengue menace across the regions expected to drive the market demand for dengue vaccine over the forecast period. Moreover, several governments are actively looking for incorporating dengue vaccine in routine immunization programmes to prevent the dengue epidemics. According to WHO estimates, there are around 50 Mn dengue infections worldwide every year and dengue is endemic in over 100 countries across the globe.
Asia-Pacific Got Significant Share
Dengue Vaccine Market-Regional Analysis
Asia-Pacific region expected to lead the global dengue vaccines market owing to widespread prevalence and incidence of dengue fever and large population, who are at dengue fever risk. Latin America expected to register highest market growth among all regions owing to the early adoption of the vaccine in government immunization programmes.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Global Dengue Vaccine Market Segmentation
By Product Type
By Vaccine Type
- Live Attenuated Vaccine
- Killed Vaccine
- Others
By End Users
- Hospitals
- Clinics
- Government Institutes
- Non-Governmental Organization (NGOs)
By Geography
- North America
- Latin America
- Europe
- Asia Pacifc
- MIddle East and Africa
Frequently Asked Questions
The Dengue vaccine market size was valued at USD 472.6 million in 2023
The Dengue vaccine market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
The Dengue vaccine market key players Takeda Pharmaceutical Company Limited, Serum Institute of India Pvt. Ltd, Panacea Biotec Limited, Sanofi Pasteur Limited, GeneOne Life Science, Sun Pharmaceutical Industries Ltd.
| 1. Executive Summary |
| 2. Global Dengue Vaccine Market Introduction |
| 2.1. Global Dengue Vaccine Market Taxonomy |
| 2.2. Global Dengue Vaccine Market Definitions |
| 2.2.1. By Product Type |
| 2.2.2. By Vaccine Type |
| 2.2.3. By End User |
| 2.2.4. By Region |
| 3. Global Dengue Vaccine Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Dengue Vaccine Market Dynamic Factors - Impact Analysis |
| 3.6. Global Dengue Vaccine Market Competition Landscape |
| 4. Global Dengue Vaccine Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Dengue Vaccine Market, By Product Type, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.1. CYD-TDV (Dengvaxia) |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. DENVax |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. TetraVax-DV |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Others |
| 5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 6. Global Dengue Vaccine Market, By Vaccine Type, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.1. Live Attenuated Vaccine |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Killed Vaccine |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Others |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7. Global Dengue Vaccine Market Forecast, By End User, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.1. Hospitals |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Clinics |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Government Institutes |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Non-Governmental Organizations (NGOs) |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 8. Global Dengue Vaccine Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 8.1. North America |
| 8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Europe |
| 8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Asia-Pacific |
| 8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Latin America |
| 8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Middle East and Africa |
| 8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 8.6. Global Dengue Vaccine Market - Opportunity Analysis Index, By Product Type, By Application, By End User, and Region, 2024 - 2030 |
| 9. North America Dengue Vaccine Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 9.1. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. CYD-TDV (Dengvaxia) |
| 9.1.2. DENVax |
| 9.1.3. TetraVax-DV |
| 9.1.4. Others |
| 9.2. Vaccine Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1. Live Attenuated Vaccine |
| 9.2.2. Killed Vaccine |
| 9.2.3. Others |
| 9.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1. Hospitals |
| 9.3.2. Clinics |
| 9.3.3. Government Institutes |
| 9.3.4. Non-Governmental Organizations (NGOs) |
| 9.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 9.4.1. USA |
| 9.4.2. Canada |
| 9.5. North America Dengue Vaccine Market - Opportunity Analysis Index, By Product Type, By Vaccine Type, By End User and Country, 2024 - 2030 |
| 9.6. North America Dengue Vaccine Market Dynamics Trends |
| 10. Europe Dengue Vaccine Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 10.1. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. CYD-TDV (Dengvaxia) |
| 10.1.2. DENVax |
| 10.1.3. TetraVax-DV |
| 10.1.4. Others |
| 10.2. Vaccine Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1. Live Attenuated Vaccine |
| 10.2.2. Killed Vaccine |
| 10.2.3. Others |
| 10.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1. Hospitals |
| 10.3.2. Clinics |
| 10.3.3. Government Institutes |
| 10.3.4. Non-Governmental Organizations (NGOs) |
| 10.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 10.4.1. Germany |
| 10.4.2. UK |
| 10.4.3. France |
| 10.4.4. Spain |
| 10.4.5. Italy |
| 10.4.6. Russia |
| 10.4.7. Benelux |
| 10.4.8. Rest of Europe |
| 10.5. Europe Dengue Vaccine Market - Opportunity Analysis Index, By Product Type, By Vaccine Type, By End User and Country, 2024 - 2030 |
| 10.6. Europe Dengue Vaccine Market Dynamics Trends |
| 11. Asia-Pacific Dengue Vaccine Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 11.1. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. CYD-TDV (Dengvaxia) |
| 11.1.2. DENVax |
| 11.1.3. TetraVax-DV |
| 11.1.4. Others |
| 11.2. Vaccine Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1. Live Attenuated Vaccine |
| 11.2.2. Killed Vaccine |
| 11.2.3. Others |
| 11.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1. Hospitals |
| 11.3.2. Clinics |
| 11.3.3. Government Institutes |
| 11.3.4. Non-Governmental Organizations (NGOs) |
| 11.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.4.1. China |
| 11.4.2. India |
| 11.4.3. Japan |
| 11.4.4. ASEAN |
| 11.4.5. Australia & New Zealand |
| 11.4.6. Rest of Asia-Pacific |
| 11.5. Asia-Pacific Dengue Vaccine Market - Opportunity Analysis Index, By Product Type, By Vaccine Type, By End User and Country, 2024 - 2030 |
| 11.6. Asia-Pacific Dengue Vaccine Market Dynamics Trends |
| 12. Latin America Dengue Vaccine Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 12.1. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. CYD-TDV (Dengvaxia) |
| 12.1.2. DENVax |
| 12.1.3. TetraVax-DV |
| 12.1.4. Others |
| 12.2. Vaccine Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1. Live Attenuated Vaccine |
| 12.2.2. Killed Vaccine |
| 12.2.3. Others |
| 12.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1. Hospitals |
| 12.3.2. Clinics |
| 12.3.3. Government Institutes |
| 12.3.4. Non-Governmental Organizations (NGOs) |
| 12.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 12.4.1. Brazil |
| 12.4.2. Mexico |
| 12.4.3. Argentina |
| 12.4.4. Rest of Latin America |
| 12.5. Latin America Dengue Vaccine Market - Opportunity Analysis Index, By Product Type, By Vaccine Type, By End User and Country, 2024 - 2030 |
| 12.6. Latin America Dengue Vaccine Market Dynamics Trends |
| 13. Middle East and Africa Dengue Vaccine Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 13.1. Product Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1. CYD-TDV (Dengvaxia) |
| 13.1.2. DENVax |
| 13.1.3. TetraVax-DV |
| 13.1.4. Others |
| 13.2. Vaccine Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1. Live Attenuated Vaccine |
| 13.2.2. Killed Vaccine |
| 13.2.3. Others |
| 13.3. End User Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1. Hospitals |
| 13.3.2. Clinics |
| 13.3.3. Government Institutes |
| 13.3.4. Non-Governmental Organizations (NGOs) |
| 13.4. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 13.4.1. Gulf Cooperation Council (GCC) Countries |
| 13.4.2. Israel |
| 13.4.3. South Africa |
| 13.4.4. Rest of MEA |
| 13.5. MEA Dengue Vaccine Market - Opportunity Analysis Index, By Product Type, By Vaccine Type, By End User and Country, 2024 - 2030 |
| 13.6. MEA Dengue Vaccine Market Dynamics Trends |
| 14. Competition Landscape |
| 14.1. Strategic Dashboard of Top Market Players |
| 14.2. Company Profiles (Introduction, Financial Analysis, Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 14.2.1. Takeda Pharmaceutical Company Limited |
| 14.2.2. Serum Institute of India Pvt. Ltd |
| 14.2.3. Panacea Biotec Limited |
| 14.2.4. Sanofi Pasteur Limited |
| 14.2.5. GeneOne Life Science |
| 14.2.6. Sun Pharmaceutical Industries Ltd. |
| 15. Research Methodology |
| 16. Key Assumptions and Acronyms |
- Takeda Pharmaceutical Company Limited
- Serum Institute of India Pvt. Ltd
- Panacea Biotec Limited
- Sanofi Pasteur Limited
- GeneOne Life Science
- Sun Pharmaceutical Industries Ltd.